Telix Pharmaceuticals Stock Current Valuation
| TLX Stock | 25.74 0.80 3.21% |
Valuation analysis of Telix Pharmaceuticals helps investors to measure Telix Pharmaceuticals' intrinsic value by examining its available valuation indicators, including the cash flow records, the balance sheet account changes and income statement patterns. At this time, Telix Pharmaceuticals' Other Non Cash Items is comparatively stable compared to the past year. Total Cash From Operating Activities is likely to gain to about 25.1 M in 2024, whereas Change In Cash is likely to drop slightly above 6.6 M in 2024. Fundamental drivers impacting Telix Pharmaceuticals' valuation include:
Price Book 21.3276 | Enterprise Value 8.5 B | Enterprise Value Ebitda 116.7546 | Price Sales 13.012 | Forward PE 21.0084 |
Undervalued
Today
Please note that Telix Pharmaceuticals' price fluctuation is very steady at this time. Calculation of the real value of Telix Pharmaceuticals is based on 3 months time horizon. Increasing Telix Pharmaceuticals' time horizon generally increases the accuracy of value calculation and significantly improves the predictive power of the methodology used.
Telix Pharmaceuticals' intrinsic value may or may not be the same as its current market price of 25.74, in which case there is an opportunity to profit from the mispricing, assuming the market price will eventually merge with its intrinsic value. | Historical | Market 25.74 | Real 28.67 | Hype 25.59 |
The intrinsic value of Telix Pharmaceuticals' stock can be calculated using various methods such as discounted cash flow analysis, price-to-earnings ratio, or price-to-book ratio. That value may differ from its current market price, which is determined by supply and demand factors such as investor sentiment, market trends, news, and other external factors that may influence Telix Pharmaceuticals' stock price. It is important to note that the real value of any stock may change over time based on changes in the company's performance.
Estimating the potential upside or downside of Telix Pharmaceuticals helps investors to forecast how Telix stock's addition to their portfolios will impact the overall performance. We also use other valuation drivers to help us estimate the true value of Telix Pharmaceuticals more accurately as focusing exclusively on Telix Pharmaceuticals' fundamentals will not take into account other important factors: Telix Pharmaceuticals Company Current Valuation Analysis
Telix Pharmaceuticals' Enterprise Value is a firm valuation proxy that approximates the current market value of a company. It is typically used to determine the takeover or merger price of a firm. Unlike Market Cap, this measure takes into account the entire liquid asset, outstanding debt, and exotic equity instruments that the company has on its balance sheet. When a takeover occurs, the parent company will have to assume the target company's liabilities but will take possession of all cash and cash equivalents.
Current Telix Pharmaceuticals Current Valuation | 8.52 B |
Most of Telix Pharmaceuticals' fundamental indicators, such as Current Valuation, are part of a valuation analysis module that helps investors searching for stocks that are currently trading at higher or lower prices than their real value. If the real value is higher than the market price, Telix Pharmaceuticals is considered to be undervalued, and we provide a buy recommendation. Otherwise, we render a sell signal.
Enterprise Value can be a useful tool to compare companies with different capital structures. Long term liability and current cash or cash equivalents can have a huge impact on market valuation of a given company.
| Competition |
In accordance with the recently published financial statements, Telix Pharmaceuticals has a Current Valuation of 8.52 B. This is much higher than that of the Biotechnology sector and significantly higher than that of the Health Care industry. The current valuation for all Australia stocks is notably lower than that of the firm.
Telix Current Valuation Peer Comparison
Stock peer comparison is one of the most widely used and accepted methods of equity analyses. It analyses Telix Pharmaceuticals' direct or indirect competition against its Current Valuation to detect undervalued stocks with similar characteristics or determine the stocks which would be a good addition to a portfolio. Peer analysis of Telix Pharmaceuticals could also be used in its relative valuation, which is a method of valuing Telix Pharmaceuticals by comparing valuation metrics of similar companies.Telix Pharmaceuticals is currently under evaluation in current valuation category among its peers.
Telix Fundamentals
| Return On Equity | 0.2 | ||||
| Return On Asset | 0.0797 | ||||
| Profit Margin | 0.08 % | ||||
| Operating Margin | 0.09 % | ||||
| Current Valuation | 8.52 B | ||||
| Shares Outstanding | 334.72 M | ||||
| Shares Owned By Insiders | 41.42 % | ||||
| Shares Owned By Institutions | 17.88 % | ||||
| Price To Book | 21.33 X | ||||
| Price To Sales | 13.01 X | ||||
| Revenue | 496.66 M | ||||
| Gross Profit | 98.54 M | ||||
| EBITDA | 22.97 M | ||||
| Net Income | 5.21 M | ||||
| Total Debt | 17.45 M | ||||
| Book Value Per Share | 1.21 X | ||||
| Cash Flow From Operations | 23.88 M | ||||
| Earnings Per Share | 0.15 X | ||||
| Target Price | 25.62 | ||||
| Beta | 2.38 | ||||
| Market Capitalization | 8.4 B | ||||
| Total Asset | 398.3 M | ||||
| Retained Earnings | (263.67 M) | ||||
| Working Capital | 67.44 M | ||||
| Net Asset | 398.3 M |
About Telix Pharmaceuticals Fundamental Analysis
The Macroaxis Fundamental Analysis modules help investors analyze Telix Pharmaceuticals's financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of Telix Pharmaceuticals using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of Telix Pharmaceuticals based on its fundamental data. In general, a quantitative approach, as applied to this company, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.
Please read more on our fundamental analysis page.
Thematic Opportunities
Explore Investment Opportunities
Additional Tools for Telix Stock Analysis
When running Telix Pharmaceuticals' price analysis, check to measure Telix Pharmaceuticals' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Telix Pharmaceuticals is operating at the current time. Most of Telix Pharmaceuticals' value examination focuses on studying past and present price action to predict the probability of Telix Pharmaceuticals' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Telix Pharmaceuticals' price. Additionally, you may evaluate how the addition of Telix Pharmaceuticals to your portfolios can decrease your overall portfolio volatility.